Analysis reveals the impact of RAS pathway mutations on overall survival after allogeneic stem cell transplantation in chronic myelomonocytic leukemia patients.
Key Points
Overall survival was significantly affected by RAS pathway mutations, influencing outcomes in chronic myelomonocytic leukemia.
Cumulative incidence analyses demonstrated that 33% of patients relapsed within two years post transplantation.
Multivariate analysis indicated that RAS pathway mutations were significantly associated with worse outcomes post SCT in CMML patients.
Allogeneic stem cell transplantation can provide durable disease control, although outcomes differ by conditioning regimens.
Cite This Study
Montalban‐Bravo et al. (2025) studied this question.